178 related articles for article (PubMed ID: 6616481)
1. Phenotypic characteristics of cells derived from precursors of human melanoma.
Herlyn M; Herlyn D; Elder DE; Bondi E; LaRossa D; Hamilton R; Sears HF; Balaban G; Guerry D; Clark WH
Cancer Res; 1983 Nov; 43(11):5502-8. PubMed ID: 6616481
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of cultured human melanocytes isolated from different stages of tumor progression.
Herlyn M; Thurin J; Balaban G; Bennicelli JL; Herlyn D; Elder DE; Bondi E; Guerry D; Nowell P; Clark WH
Cancer Res; 1985 Nov; 45(11 Pt 2):5670-6. PubMed ID: 4053039
[TBL] [Abstract][Full Text] [Related]
3. Tumor progression in the human melanocytic system.
Kath R; Rodeck U; Menssen HD; Mancianti ML; Linnenbach AJ; Elder DE; Herlyn M
Anticancer Res; 1989; 9(4):865-72. PubMed ID: 2554787
[TBL] [Abstract][Full Text] [Related]
4. Tumor progression in melanoma: the biology of epidermal melanocytes in vitro.
Mancianti ML; Herlyn M
Carcinog Compr Surv; 1989; 11():369-86. PubMed ID: 2646021
[TBL] [Abstract][Full Text] [Related]
5. The initial steps of tumor progression in melanocytic lineage: a histochemical approach.
Wollina U; Kilian U; Henkel U; Schaarschmidt H; Knopf B
Anticancer Res; 1991; 11(4):1405-14. PubMed ID: 1746897
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the role of melanoma growth stimulatory activity (MGSA) in the growth of normal melanocytes, nevocytes, and malignant melanocytes.
Bordoni R; Fine R; Murray D; Richmond A
J Cell Biochem; 1990 Dec; 44(4):207-19. PubMed ID: 2095366
[TBL] [Abstract][Full Text] [Related]
7. Recombinant gamma-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells.
Herlyn M; Guerry D; Koprowski H
J Immunol; 1985 Jun; 134(6):4226-30. PubMed ID: 2985706
[TBL] [Abstract][Full Text] [Related]
8. Nevi, other than dysplastic and Spitz nevi.
Cochran AJ; Bailly C; Paul E; Dolbeau D
Semin Diagn Pathol; 1993 Feb; 10(1):3-17. PubMed ID: 8506415
[TBL] [Abstract][Full Text] [Related]
9. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000.
Lehmann JM; Holzmann B; Breitbart EW; Schmiegelow P; Riethmüller G; Johnson JP
Cancer Res; 1987 Feb; 47(3):841-5. PubMed ID: 3542195
[TBL] [Abstract][Full Text] [Related]
10. Micro-anatomy related antigen expression in melanocytic lesions.
Meije CB; Mooi WJ; Le Poole IC; Van Muijen GN; Das PK
J Pathol; 2000 Apr; 190(5):572-8. PubMed ID: 10727983
[TBL] [Abstract][Full Text] [Related]
11. Malignant melanoma and nevocellular nevi. Histogenesis and relationships. Fluorescence-microscopic and catamnestic photographic studies.
Paul E
Norm Pathol Anat (Stuttg); 1984; 48():1-112. PubMed ID: 6701085
[TBL] [Abstract][Full Text] [Related]
12. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
13. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
Fullen DR; Zhu W; Thomas D; Su LD
J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
[TBL] [Abstract][Full Text] [Related]
14. Growth and phenotypic characteristics of human nevus cells in culture.
Mancianti ML; Herlyn M; Weil D; Jambrosic J; Rodeck U; Becker D; Diamond L; Clark WH; Koprowski H
J Invest Dermatol; 1988 Feb; 90(2):134-41. PubMed ID: 2828480
[TBL] [Abstract][Full Text] [Related]
15. Fine structural characterization of melanosomes in dysplastic nevi.
Takahashi H; Horikoshi T; Jimbow K
Cancer; 1985 Jul; 56(1):111-23. PubMed ID: 4005780
[TBL] [Abstract][Full Text] [Related]
16. Detection of p53 mutations in benign and dysplastic nevi.
Levin DB; Wilson K; Valadares de Amorim G; Webber J; Kenny P; Kusser W
Cancer Res; 1995 Oct; 55(19):4278-82. PubMed ID: 7671235
[TBL] [Abstract][Full Text] [Related]
17. Malignant melanoma, dysplastic melanocytic nevi, and Spitz tumors. Histologic classification and characteristics.
Barnhill RL
Clin Plast Surg; 2000 Jul; 27(3):331-60, viii. PubMed ID: 10941557
[TBL] [Abstract][Full Text] [Related]
18. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
19. Melanocytic nevi with features of Spitz nevi and Clark's/dysplastic nevi ("Spark's" nevi).
Ko CJ; McNiff JM; Glusac EJ
J Cutan Pathol; 2009 Oct; 36(10):1063-8. PubMed ID: 19187111
[TBL] [Abstract][Full Text] [Related]
20. Malignant melanoma simulants arising in congenital melanocytic nevi do not show experimental evidence for a malignant phenotype.
Mancianti ML; Clark WH; Hayes FA; Herlyn M
Am J Pathol; 1990 Apr; 136(4):817-29. PubMed ID: 2327470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
